Copyright © 2013 American Medical Association. All rights reserved. From: Patient-Reported Visual Function Outcomes Improve After Ranibizumab Treatment in Patients With Vision Impairment Due to Diabetic Macular EdemaRandomized Clinical Trial JAMA Ophthalmol. 2013;131(10):1339-1347. doi:10.1001/jamaophthalmol.2013.4592 Figure Legend: Patient Disposition for Completion of the National Eye Institute Visual Functioning Questionnaire 25 (NEI VFQ-25) in the Ranibizumab Monotherapy or Combined With Laser vs Laser Monotherapy for Diabetic Macular Edema TrialData are provided for the full analysis set. One patient in the ranibizumab plus laser group had no baseline NEI VFQ-25 data. The 12-month data are reported without last observation carried forward; with the last observation carried forward only 4 patients were lost after baseline. Date of download: 11/5/2017 Copyright © 2013 American Medical Association. All rights reserved.

Copyright © 2013 American Medical Association. All rights reserved. From: Patient-Reported Visual Function Outcomes Improve After Ranibizumab Treatment in Patients With Vision Impairment Due to Diabetic Macular EdemaRandomized Clinical Trial JAMA Ophthalmol. 2013;131(10):1339-1347. doi:10.1001/jamaophthalmol.2013.4592 Figure Legend: Mean Change From Baseline to 12 Months in National Eye Institute Visual Functioning Questionnaire 25 (NEI VFQ-25) Composite and Subscale ScoresA, Mean change from baseline to 12 months in NEI VFQ-25 scores. B, NEI VFQ-25 composite score and general vision subscales. C, NEI VFQ-25 near activities and distance activities subscales. Error bars indicate upper 95% confidence limit. aP < .05.bP ≤ .001 vs laser. Date of download: 11/5/2017 Copyright © 2013 American Medical Association. All rights reserved.

Copyright © 2013 American Medical Association. All rights reserved. From: Patient-Reported Visual Function Outcomes Improve After Ranibizumab Treatment in Patients With Vision Impairment Due to Diabetic Macular EdemaRandomized Clinical Trial JAMA Ophthalmol. 2013;131(10):1339-1347. doi:10.1001/jamaophthalmol.2013.4592 Figure Legend: Mean Change From Baseline to 12 Months in Composite National Eye Institute Visual Functioning Questionnaire 25 (NEI VFQ-25) Scores by SubgroupsA, Baseline visual acuity (VA). B, Better-seeing eye (BSE) or worse-seeing eye (WSE) as the treated eye. C, Baseline VA according to BSE or WSE as the study eye. D, Baseline central retinal (subfield) thickness (CRT). E, Median NEI VFQ-25 composite score. Error bars indicate upper 95% confidence limit. aP < .05. Date of download: 11/5/2017 Copyright © 2013 American Medical Association. All rights reserved.